Search results for " Embolism"

showing 10 items of 311 documents

Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2) : a multinational, multicentre, single-ar…

2021

BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. …

Malemedicine.medical_specialtyPopulationAdministration OralHemorrhage030204 cardiovascular system & hematologyDrug Administration ScheduleDabigatran03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyRIGHT-VENTRICULAR DYSFUNCTION VENOUS THROMBOEMBOLISM DABIGATRAN MANAGEMENT WARFARIN HOSPITALIZATION RATIONALE HEPARIN DESIGNHeparinbusiness.industryAnticoagulantsVenous ThromboembolismHematologyGuidelineHeparinMiddle AgedInterim analysismedicine.diseaseThrombosisDabigatran3. Good healthPulmonary embolismClinical trialTreatment OutcomeFemalePulmonary EmbolismbusinessFollow-Up Studiesmedicine.drug
researchProduct

Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis

2012

Abstract Introduction Oral thromboprophylaxis with dabigatran etexilate should be initiated as a half dose 1 to 4 h after major orthopaedic surgery. However, a delay in dosing could occur for clinical or logistical reasons. A post hoc analysis was carried out to determine if patients with delayed dosing received adequate anticoagulation. Patients and methods The RE-MODEL™ and RE-NOVATE® trials compared 220 mg and 150 mg dabigatran etexilate with 40 mg enoxaparin. Pooled data for major venous thromboembolism (VTE) and VTE-related mortality (efficacy outcome) and major bleeding events (MBE), MBE/clinically relevant bleeding events, and all bleeding events (safety outcomes) were analysed. Resu…

Malemedicine.medical_specialtyPyridinesAntithrombinsDrug Administration ScheduleDabigatranlaw.inventionDouble-Blind MethodRandomized controlled triallawPost-hoc analysisHumansMedicineOrthopedic ProceduresProspective StudiesDosingEnoxaparinProspective cohort studyAgedbusiness.industryAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseDabigatranPulmonary embolismTreatment OutcomeAnesthesiaOrthopedic surgeryBenzimidazolesFemalebusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Radiographic and chest CT imaging presentation and follow-up of COVID-19 pneumonia: a multicenter experience from an endemic area.

2020

COVID-19 has infected more than 2 million people in the world in less than 5 months outbreak. Chest imaging is recommended for triage of suspected cases of COVID-19 with moderate-severe clinical features and high pre-test probability of disease, and may help for patient follow-up and to identify patients at higher risk of disease worsening. This pictorial essay illustrates typical and uncommon imaging findings of COVID-19 pneumonia and the role of imaging for patient management.

Malemedicine.medical_specialtyRadiographyPneumonia ViralDiseaseCoronavirus infections030218 nuclear medicine & medical imaging03 medical and health sciencesBetacoronavirus0302 clinical medicinePandemicCoronavirus infectionmedicineHumansRadiology Nuclear Medicine and imagingPandemicsAgedAged 80 and overbusiness.industrySARS-CoV-2Pulmonary embolismOutbreakCOVID-19030208 emergency & critical care medicineMiddle Agedmedicine.diseaseTriagePulmonary embolismCoronavirus disease 2019 (COVID-19)PneumoniaItalyRadiology Nuclear Medicine and imagingEmergency MedicinePictorial EssayFemaleRadiography ThoracicRadiologyPresentation (obstetrics)Settore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessTomography X-Ray ComputedCTEmergency radiology
researchProduct

The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism.

2013

Heart-type fatty acid-binding protein (H-FABP) is a useful biomarker for risk stratification of patients with pulmonary embolism (PE). In patients with acute myocardial infarction, H-FABP plasma concentrations rise after 30 minutes and return to normal within 20-24 hours. We tested whether the predictive value of H-FABP is affected by the duration of symptoms prior to diagnosis in patients with PE.We prospectively studied 257 consecutive normotensive patients with confirmed symptomatic PE.Patients with acute (24 hours; n=150) symptom onset presented more often with syncope (28.7% vs. 6.5%; p0.001) compared to patients with symptoms ≥ 24 hours (n=107); other baseline characteristics, comorbi…

Malemedicine.medical_specialtyRenal function030204 cardiovascular system & hematologyFatty Acid-Binding Proteins03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedbusiness.industryArea under the curveHematologyOdds ratioMiddle Agedmedicine.diseasePrognosisConfidence interval3. Good healthPulmonary embolismHeart-type fatty acid binding proteinCardiologyBiomarker (medicine)lipids (amino acids peptides and proteins)FemalebusinessPulmonary EmbolismFatty Acid Binding Protein 3Thrombosis research
researchProduct

Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards

2010

Abstract Introduction Current guidelines for ischemic stroke prevention in atrial fibrillation or flutter (AFF) recommend Vitamin K antagonists (VKAs) for patients at high-intermediate risk and aspirin for those at intermediate-low risk. The cost-effectiveness of these treatments was demonstrated also in elderly patients. However, there are several reports that emphasize the underuse of pharmacological prophylaxis of cardio-embolism in patients with AFF in different health care settings. Aims To evaluate the adherence to current guidelines on cardio-embolic prophylaxis in elderly (> 65 years old) patients admitted with an established diagnosis of AFF to the Italian internal medicine wards p…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaVitamin Kantithrombotic therapyNOAntithrombotic prophylaxis Atrial fibrillation Platelet agents Vitamin K antagonistsFibrinolytic AgentsRisk FactorsInternal medicineAntithromboticInternal MedicinemedicineHumansatrial fibrillationRegistriesMedical prescriptionStrokeAgedRetrospective StudiesAged 80 and overAntithrombotic prophylaxis; Atrial fibrillation; Platelet agents; Vitamin K antagonists;guidelines; antithrombotic therapy; atrial fibrillation.AspirinAspirinbusiness.industryantithrombotic prophylaxis; atrial fibrillation; platelet agents; vitamin k antagonistsAtrial fibrillationRetrospective cohort studyplatelet agentsmedicine.diseaseStrokevitamin k antagonistsIntracranial EmbolismItalyPlatelet aggregation inhibitorFemaleGuideline Adherenceantithrombotic prophylaxisbusinessguidelinePlatelet Aggregation InhibitorsFibrinolytic agentatrial fibrillation.medicine.drug
researchProduct

A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study

2015

Superficial vein thrombosis (SVT) is commonly encountered in clinical practice. Recent studies have suggested that the concomitant presence of deep vein thrombosis (DVT) or pulmonary embolism (PE) at the time of SVT diagnosis is not uncommon, thus increasing the interest on this disease. Whether this coexistence is predicted by specific risk factors remains unknown.To evaluate potential risk factors for DVT coexistence in patients presenting with acute objectively diagnosed SVT of the lower limbs and to develop a simple score entirely based on clinical variables to define the pre-test probability of DVT in these patients.A multicenter, retrospective cohort study on SVT patients was conducte…

Malemedicine.medical_specialtySuperficial vein thrombosisDeep veinCohort StudiesMedicinePulmonary embolism; Risk factors; Saphenous vein; Ultrasonography; Venous thrombosis;Humanscardiovascular diseasesUltrasonographyRetrospective StudiesVenous Thrombosisbusiness.industryPulmonary embolismRetrospective cohort studyHematologySaphenous veinPulmonary embolism; Risk factors; Saphenous vein; Ultrasonography; Venous thrombosis; Cohort Studies; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Venous ThrombosisMiddle Agedmedicine.diseaseVenous thrombosiThrombosisPulmonary embolismVenous thrombosismedicine.anatomical_structureRisk factorsConcomitantFemaleRadiologyRisk factorbusinessCohort study
researchProduct

Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

2014

This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥75), and the overall population (All) from a US Medicare payer perspective. Clinical event rates by age cohort with dabigatran or warfarin for safety-on-treatment and intent-to-treat populations were estimated from Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY). An economic model was adapted using these data to evaluate the impact of starting age on clinical and economic outcomes. Costs were obtained from Medicare p…

Malemedicine.medical_specialtyTime FactorsCost effectivenessCost-Benefit AnalysisMedicareAntithrombinsDrug Administration ScheduleDrug CostsDabigatranThromboembolismInternal medicineAtrial FibrillationmedicineHumansIn patientcardiovascular diseasesStrokeAgedbusiness.industryIncidenceFollow up studiesWarfarinSystemic embolismAtrial fibrillationPrognosismedicine.diseaseUnited StatesDabigatranbeta-AlanineCardiologyBenzimidazolesFemalebusinessCardiology and Cardiovascular MedicineFollow-Up Studiesmedicine.drugThe American Journal of Cardiology
researchProduct

Quality of life and functional limitations after pulmonary embolism and its prognostic relevance

2019

Abstract Background While the importance of patients’ quality of life (QoL) in chronic cardiac or pulmonary disease is uncontroversial, the burden of an acute pulmonary embolism (PE) on QoL has received little attention thus far. Objectives We aimed to validate the German PEmb‐QoL questionnaire, identify associations between QoL and clinical/functional parameters, and investigate the prognostic relevance of QoL for long‐term survival in survivors of an acute PE episode. Patients/Methods Patients were invited for a clinical follow‐up visit including assessment of QoL using the German PEmb‐QoL questionnaire 6 months after an objectively confirmed PE at a single center. Internal consistency re…

Malemedicine.medical_specialtyTime FactorsPsychometricsPsychometricsHealth Status030204 cardiovascular system & hematologySingle Center03 medical and health sciences0302 clinical medicineCost of IllnessQuality of lifePredictive Value of TestsRisk FactorsInterquartile rangeGermanySurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesSurvivorsProspective cohort studyDepression (differential diagnoses)Agedbusiness.industryReproducibility of ResultsOriginal ArticlesHematologyMiddle AgedPrognosismedicine.diseasehumanities3. Good healthPulmonary embolismTHROMBOSISDyspneaPredictive value of testsQuality of LifeFemaleOriginal ArticleSymptom AssessmentPulmonary Embolismbusiness
researchProduct

Early extubation followed by immediate noninvasive ventilation vs. standard extubation in hypoxemic patients: a randomized clinical trial

2018

Purpose: Noninvasive ventilation (NIV) may facilitate withdrawal of invasive mechanical ventilation (i-MV) and shorten intensive care unit (ICU) length of stay (LOS) in hypercapnic patients, while data are lacking on hypoxemic patients. We aim to determine whether NIV after early extubation reduces the duration of i-MV and ICU LOS in patients recovering from hypoxemic acute respiratory failure. Methods: Highly selected non-hypercapnic hypoxemic patients were randomly assigned to receive NIV after early or standard extubation. Co-primary end points were duration of i-MV and ICU LOS. Secondary end points were treatment failure, severe events (hemorrhagic, septic, cardiac, renal or neurologic …

Malemedicine.medical_specialtyTime FactorsSedationmedicine.medical_treatmentWeaningAcute respiratory failureCritical Care and Intensive Care Medicinelaw.inventionHypoxemia03 medical and health sciences0302 clinical medicineTracheotomylawExtubationAnesthesiologymedicineHumansHypoxiaAgedMechanical ventilationChi-Square Distributionbusiness.industry030208 emergency & critical care medicineLength of StayMiddle Agedmedicine.diseaseIntensive care unitRespiration ArtificialPulmonary embolismIntensive Care Units030228 respiratory systemPneumothoraxItalyAnesthesiaBreathingAirway ExtubationFemalemedicine.symptomBlood Gas AnalysisbusinessVentilator WeaningNoninvasive ventilation
researchProduct

Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany.

2019

Abstract Aims Pulmonary embolism (PE) is the third most common cardiovascular cause of death; systemic thrombolysis is potentially lifesaving treatment in patients presenting with haemodynamic instability. We investigated trends in the use of systemic thrombolysis and the outcome of patients with acute PE. Methods and results We analysed data on the characteristics, comorbidities, treatment, and in-hospital outcome of 885 806 PE patients in Germany between 2005 and 2015. Incidence of acute PE was 99/100 000 population/year and increased from 85/100 000 in 2005 to 109/100 000 in 2015 [β 0.32 (0.26–0.38), P &amp;lt; 0.001]. During the same period, in-hospital case fatality rates decreased fro…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicineGermanyCase fatality ratemedicineHumansThrombolytic TherapyCardiopulmonary resuscitationHospital MortalityeducationCause of deathAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryMortality rate030229 sport sciencesThrombolysisMiddle Agedmedicine.diseasePulmonary embolismTreatment OutcomeAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFibrinolytic agentFollow-Up StudiesEuropean heart journal
researchProduct